This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers

This study has been withdrawn prior to enrollment.
Information provided by:
Pfizer Identifier:
First received: November 30, 2010
Last updated: October 15, 2015
Last verified: October 2015
This study investigates the safety, tolerability and pharmacokinetics of PF-04191834 when respectively given orally as a single dispersion dose and a single dose of a suspension. The suspension is the test formulation and the dispersion is the formulation with which the novel preparation will be compared.

Condition Intervention Phase
Healthy Drug: PF-04191834 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: An Open Label, Randomized 3-Way Crossover Single Dose Study To Compare The Pharmacokinetics And Relative Bioavailability Of PF-04191834 Using An Oral Wet-Milled Suspension Formulation Versus An Oral Single Dose Dispersion Formulation Under Fasted Conditions In Healthy Volunteers

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Time of maximum concentration(Tmax) of PF-04191834 in plasma. [ Time Frame: 3 days ]
  • Area under the curve (AUClast) from the time of dosing to the last data point taken for PF-04191834. [ Time Frame: 3 days ]
  • Area under the curve from the time of dosing extrapolated to infinity(AUCinf) of PF-04191834. [ Time Frame: 3 days ]

Secondary Outcome Measures:
  • Maximum concentration (Cmax) for PF-04191834 in plasma. [ Time Frame: 3 days ]
  • Elimination half-life (t1/2) of PF-04191834 [ Time Frame: 3 days ]
  • Sheehan suicidality tracking scale (SSTS) [ Time Frame: Screening and last Day of Period 3 ]
  • Number of adverse events in patients as a measure of safety and tolerability. [ Time Frame: Throughout the study. ]

Enrollment: 0
Study Start Date: December 2010
Estimated Study Completion Date: January 2011
Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: oral single dose dispersion 100mg
Subjects receive a single dose of PF-04191834 as a dispersion
Drug: PF-04191834
single dose, 100mg, dispersion
Active Comparator: oral wet milled suspension 100mg
Subjects receive a single dose of PF-04191834 as a suspension
Drug: PF-04191834
single dose, 100mg, suspension
Active Comparator: oral wet milled suspension 300mg
Subjects receive a single dose of PF-04191834 as a suspension
Drug: PF-04191834
single dose, 300mg, suspension


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG or clinical laboratory tests.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg(110 lbs).

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Clinical evidence of existing hepatic disease or a medical history of such a condition in the last year. Subjects with AST or ALT >ULN. Subjects with total bilirubin >ULN (except those with a documented history of Gilbert's Syndrome). Subjects with AST/ALT/total bilirubin >ULN and <1.5X ULN may be retested once.
  • Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication;
  • Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day;
  • Females of childbearing potential.
  • Subjects with positive responses (score 1) for suicidality on the Sheehan Suicidality Tracking Scale (S-STS) (specifically items 1a, 1b, 3, 4, 5, 6, 7, or 9).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01265732

Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT01265732     History of Changes
Other Study ID Numbers: B0041012
Study First Received: November 30, 2010
Last Updated: October 15, 2015

Keywords provided by Pfizer:
Phase 1
relative bioavailability
healthy volunteers
dispersion processed this record on July 27, 2017